This small-cap biotech may very well revolutionize how we treat depression.
News & Analysis: COMPASS Pathways plc
The company's fresh look at psychedelic drugs is attracting lots of attention.
The market is in its early stage, and the players in the space could have a lot of room to run.
Oregon just decriminalized the use of the psychedelic compound psilocybin. Could Compass Pathways, which is testing a synthetic form of the drug as a mental health therapy, be on the cusp of something big?
CMPS earnings call for the period ending September 30, 2020.
Oregon became the first state in the nation to legalize the therapeutic use of psychedelic mushrooms, raising awareness for this biotech's trailblazing treatment.
Voters in Oregon approved a ballot measure that legalizes a treatment this newly public company has in clinical trials.
The trailblazing company studying the use of the psychedelic drug found in magic mushrooms to treat mental health is starting to make waves.
A short-seller likes the recent IPO stock.